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Abstract 
BACKGROUND: Non-Valvular Atrial Fibrillation (AF) patients show high residual cardiovascular risk 
despite oral anticoagulants. Urinary 11-dehydro-thromboxane B2 (TxB2) is associated with an 
increased risk of cardiovascular events (CVEs), but its predictive value in anticoagulated AF 
patients is unknown. 
METHODS: Prospective single-center cohort study, including 837 AF patients. Mean time of follow-
up was 30.0 months yielding 2062 person-years of observation. Urinary 11-dehydro-TxB2 was 
measured at baseline. The primary end-point was the occurrence of a CVE including fatal/nonfatal 
myocardial infarction (MI) and ischemic stroke, transient ischemic attack, cardiac revascularization 
and cardiovascular death. 
RESULTS: Mean age of patients was 73.1 years, and 43.6% were women. Median 11-dehydro-TxB2 
levels were 100 [IQR 50 -187] ng/mg of urinary creatinine. Overall, the anticoagulation control was 
adequate (63.9% of mean time in therapeutic range). A CVE occurred in 99 (11.8%) patients, 55 
were CV deaths. At baseline, 11-dehydro-TxB2 levels were higher in patients with a CVE compared 
to those without (186 [107-400] vs. 98 [52-170], p<0.001). An increased rate of CVEs (Log-Rank 
test, p<0.001) and CV deaths (p<0.001) was observed across tertiles of 11-dehydro-TxB2.  
CVEs were associated with age (Hazard Ratios [HR]: 1.72 per 1SD, 95% Confidence Interval [CI] 
1.33 -2.21, p<0.001), diabetes mellitus (HR: 1.89 95%CI 1.20-2.96, p=0.005), heart failure (HR: 
1.60, 95%CI 1.01-2.54, p=0.044), history of stroke/transient ischemic attack (HR: 1.96, 95%CI 
1.25-3.06, p=0.003) and 11-dehydro-TxB2 (HR: 1.64 per 1 SD, 95%CI 1.42-1.89, p<0.001). 
CONCLUSIONS: Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV 
mortality in AF patients despite anticoagulant treatment. 
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Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia that is associated with a high risk of 
cardiovascular events and increased morbidity and mortality.1 Ischemic cardiovascular events are 
primarily localized in the cerebral circulation, where AF is particularly associated with ischemic 
stroke2.  Indeed, ischemic stroke related to AF is more severe, with a greater mortality and 
morbidity due to disability and longer hospital stays3. 
AF patients are characterized by various atherosclerotic risk factors including arterial hypertension 
and coronary artery disease, resulting in a high risk of myocardial infarction (MI).4, 5 Indeed, 
amongst elderly AF patients with high CHA2DS2-VASc score, the risk of MI is similar to that of 
stroke6. For this reason, AF patients are often treated with a combination of oral anticoagulants 
(OACs) and aspirin, which inhibits platelet thromboxane A2. Despite an unclear evidence of 
meaningful net clinical advantage,7 a large number of AF patients are often treated with OACs and 
aspirin, resulting in an associated high risk of serious bleeding.8 Recent registry data (ORBIT-AF)9 
reported that a combination of OACs with aspirin was observed in 35% of patients but the 
rationale for the use of such a combination was unclear. In more than one third, there was no 
evidence of any atherosclerotic disease, suggesting poor definition of potentially ‘high risk’ 
candidates for combination therapy with OACs plus aspirin. 
Urinary levels of 11-dehydro-thromboxane B2 (TxB2), a stable metabolite of thromboxane A2, are a 
reflection of thromboxane A2 body generation
10 and its inhibition by aspirin.11 Previous studies in 
patients at risk, or with previous cardiovascular events (CVEs) have shown that urinary 11-dehydro-
TxB2 levels are associated with CVEs including stroke, MI and cardiovascular deaths, suggesting 
that this biomarker may identify patient categories in which suppression of thromboxane A2 
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generation is of potential clinical benefit.12 Until now, the value of measuring urinary 11-dehydro-
TxB2 in anticoagulated patients with AF is unknown. 
We hypothesized that urinary 11-dehydro-TxB2 levels could be useful to identify AF patients on 
OACs who are at high residual risk of cardiovascular events. To evaluate this hypothesis, we 
performed a prospective cohort study in which the relationship between urinary 11-dehydro-TxB2 
and cardiovascular events was investigated in anticoagulated AF patients, who underwent a mean 
follow-up of 30.0 months. Second, we also assessed the clinical factors associated with urinary 11-
dehydro-TxB2 levels.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
6 
 
Materials and Methods 
Study design and patient selection. 
This prospective single-center cohort study included 950 patients with AF who were referred to 
the Atherothrombosis Center of the Department of Internal Medicine and Medical Specialties of 
Sapienza-University of Rome from February 2008 to October 2013. Included patients received oral 
vitamin K antagonists according to the CHA2DS2-VASc score.
13 International normalized ratio was 
maintained in a therapeutic range of 2.0–3.0 and time in therapeutic range (TTR) was calculated. 
Patients taking warfarin and an antiplatelet drug were eligible. 
Exclusion criteria at baseline included: presence of prosthetic heart valves, cardiac stent 
placement in the previous year, severe cognitive impairment, chronic infectious diseases, 
autoimmune systemic diseases and active cancer. Patients treated with antiplatelet agents alone 
were also excluded, as well as patients with a cardiac revascularization in the previous year. 
At enrollment, medical history and anthropometric data were recorded and a sample of urine was 
collected from all patients. Arterial hypertension was defined as elevated blood pressure 
(≥140/≥90 mmHg) or taking antihypertensive therapy;14 diabetes mellitus as a random plasma 
glucose ≥200 mg/dl, or fasting plasma glucose ≥126 mg/dl, or use of anti-diabetic treatment.15 
Heart failure was defined as the presence of signs and symptoms typical of heart failure or 
reduced ejection fraction (≤40%).16 
Follow-up 
All patients were followed-up for the entire duration of the study and outcome events were 
recorded. Patients were regularly seen at each control for INR monitoring every 20-40 days at the 
Atherothrombosis Center. Patients missing INR control were contacted and information about 
vital status and hospitalizations were recorded. Follow-up data were obtained by review of 
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hospital databases, medical records, death certificates, telephone interviews or general 
practitioners. 
Outcome Events. The occurrence of CVEs was considered as the primary outcome of the study. 
CVEs included fatal and nonfatal ischemic stroke, fatal and nonfatal MI, transient ischemic attack 
(TIA), cardiac revascularization/coronary artery bypass surgery and cardiovascular death. Diagnosis 
of MI was made according to the international definition.17 The occurrence of ischemic stroke was 
determined on clinical manifestations and confirmed by radiological findings; TIA was defined 
according to the Classification of Cerebrovascular Diseases III.18 If a patient died within 4 weeks of 
stroke or MI, this event was recorded as fatal stroke or fatal MI. Cardiovascular death included 
sudden death; progressive congestive heart failure; procedure related death (surgical or 
percutaneous revascularization); and presumed cardiovascular deaths (i.e. those for which a non-
cardiovascular cause had not been clearly established). Only the first event that occurred during 
follow-up was used in the analysis. Bleeding events were classified according to the International 
Society on Thrombosis and Haemostasis.19 
Adjudication of outcomes. Data on CVEs were prospectively collected during follow-up. When a 
CVE occurred, a standardized form was filled in by the investigators. Details on CVEs were 
registered, as well as death certificates, hospital discharge letter or copy of the medical records of 
hospitalization, and other clinical documentation (i.e. radiology and laboratory data) were also 
obtained from patients, or in case of death, from relatives of patients or from general practitioner. 
Adjudication of cardiovascular events was performed by a committee composed by three 
physicians (FV, PP, RC) who did not participate to the recruitment of patients and was unaware of 
the clinical and laboratory characteristics of any enrolled patient. Each member of the committee 
independently evaluated and adjudicated CVEs in a blinded manner. In case of discordant 
evaluation, adjudication of an event was made after a shared review of available clinical data. 
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All patients provided a written informed consent. The study protocol was approved by the local 
ethical board of Sapienza-University of Rome and was conducted according to principles of the 
Declaration of Helsinki20. This work was supported by Sapienza University of Rome, Grant Code 
“Pignatelli Progetto Ricerca Sapienza 2011”. No extramural funding was used to support this 
work. The authors are solely responsible for the design and conduct of this study, all study 
analyses, the drafting and editing of the paper and its final contents. 
Laboratory analyses. The concentration of urinary 11-dehydro-TxB2 was measured by an ELISA 
commercial kit (Cayman). Data are expressed as ng/mg creatinine. Intra- and inter-assay 
coefficients of variation were 4.0% and 3.6%, respectively. Analyses were performed in a blinded 
manner. Thus, the biologist (RC) who analyzed the samples was not aware of clinical 
characteristics of AF patients, or of CVEs. Moreover, 20% of samples were randomly selected and 
re-analyzed by a second biologist (SB), and results were compared by a third one (CN).  
Statistical analysis. Categorical variables were reported as counts (percentage). Following a test of 
statistical normality, continuous variables were expressed as mean ± standard deviation (SD) or 
median and interquartile range (IQR) unless otherwise indicated. Independence of categorical 
variables was tested with the χ2 test. The normal distribution of parameters was assessed by 
Kolmogorov–Smirnov test. Student unpaired t test and Pearson product-moment correlation 
analyses were used for normally distributed continuous variables. Appropriate nonparametric 
tests (Mann-Whitney U test and Spearman rank correlation test) were used for all the other 
variables. Group comparisons were performed using Fisher’s F-test (ANOVA) or Kruskall-Wallis test 
when needed. After dividing the AF population into tertiles according to urinary 11-dehydro-TxB2 
values, univariate analyses comparing clinical characteristics among tertiles of 11-dehydro-TxB2 
was performed. The cumulative incidence was estimated using a Kaplan–Meier product-limit 
estimator. Survival curves were formally compared using the log-rank test. The association 
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between tertiles of 11-dehydro-TxB2 levels and outcomes was examined for both CVEs and CV 
deaths separately. Cox proportional hazards analyses were used to calculate the adjusted relative 
hazards of CVEs and CV deaths by each clinical variable. The multivariable analyses were 
determined including pre-specified variables and using urinary 11-dehydro-TxB2 as continuous 
variable. Thus, in addition to 11-dehydro-TxB2 levels, the following variables were entered as 
covariates: age, smoking, arterial hypertension (treated), diabetes, history of MI, history of 
stroke/TIA, heart failure, treatment with antiplatelet agents and statins. 
Risk prediction metrics. Calibration was assessed by comparing predicted and expected events at 
each time point. Discrimination and risk reclassification were assessed by means of C-index, 
difference in C-index with a model without TxB2, and Integrated Discrimination Improvement (IDI) 
index for censored data.21, 22 The proportionality of hazards assumption for the Cox model has 
been checked using plots of Schoenfeld residuals.  
Finally, we used B-splines to identify a threshold according to Molinari et al.23, but no threshold 
was detected. 
P values <0.05 were considered as statistically significant. All tests were two-tailed and analyses 
were performed using computer software packages (SPSS-18.0, SPSS Inc. and R version 2.15.2).  
Sample size calculation. The sample size was planned using a log-rank test for comparing the first 
and third tertile of urinary 11-dehydro-TxB2. We planned a power of 80% and a type-I error rate of 
5% and a difference in the rate from 0.93 to 0.85. Therefore, 53 events in the first and last tertile 
combined were planned in order to guarantee the prescribed power. 
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Results 
Of the 950 AF patients screened, 20 patients refused to be included in the study. Based on the 
above-mentioned exclusion criteria, 71 patients were excluded and 22 patients were lost at 
follow-up. Thus, 837 AF patients were finally included in the study cohort. All patients were 
followed for a mean time of 30.0 (±21.5) months, yielding 2064 person-years of observation. Mean 
age was 73.1±8.6 years, 43.6% were women. Median CHA2DS2-VASc score was 3 [2-4] (table 1). 
Overall, the mean TTR was adequate (63.9 ± 17.1%). In the whole cohort, median 11-dehydro-TxB2 
levels were 100 [IQR 50 -187] ng/mg of urinary creatinine.  
Correlates of urinary 11-dehydro-TxB2 levels 
To better stratify AF patients, we divided our study cohort into three groups based to tertiles of 
11-dehydro-TxB2 levels: <70 ng/mg creatinine for first tertile, 70-150 ng/mg creatinine for the 
second tertile and >150 ng/mg creatinine for the third tertile. 
As shown in table 2, a significant difference among tertiles of urinary 11-dehydro-TxB2 was found 
for CHA2DS2-VASc score, HAS-BLED score and use of β blockers agents. No difference in TTR was 
detected among  the tertiles of  urinary 11-dehydro-TxB2. 
Multivariable stepwise linear regression analysis of factors associated with logarithm of urinary 
11-dehydro-TxB2 demonstrated that history of MI was positively associated with 11-dehydro-TxB2 
levels (β=0.11, p=0.006), whilst antiplatelet use was inversely associated (β=-0.10, p=0.012). All 
other factors were not significant. 
Relationship to outcomes 
A CVE occurred in 99 patients (11.8%): non-fatal MI in 11, stent/CABG in 15, ischemic non-fatal 
stroke in 16, TIA in 2, and cardiovascular deaths in 55 (including 12 fatal MI and 6 fatal ischemic 
strokes). Table 1 depicts the clinical characteristics of the study cohort, in relation to 
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presence/absence of CVEs. Mean TTR was non-significantly lower in patients with and without 
CVEs (Table 1). Those sustaining CVEs were older, with more diabetes, heart failure, a clinical 
history complicated by cardiac and cerebrovascular events and higher CHA2DS2-VASc score (Table 
1).  
Urinary 11-dehydro-TxB2 levels were higher in patients with CVEs during the follow-up (p<0.001) 
(Table 1). Similarly, urinary 11-dehydro-TxB2 levels were significantly higher in patients with 
cardiovascular death (186 [120-387] vs. 100 [55-180] ng/mg of urinary creatinine, p<0.001). 
Kaplan-Meier analysis demonstrated a significantly increased rate of CVEs (Log-Rank test: p<0.001. 
Figure 1) and cardiovascular deaths (Log-Rank test: p<0.001) across tertiles of 11-dehydro-TxB2. 
Thus, 13 CVEs occurred in the first, 24 in the second, and 61 in the third tertile of 11-dehydro-TxB2. 
Using a Cox proportional hazards analysis (table 3, panel A), CVEs were associated with age 
(Hazard Ratios [HR]: 1.72 per 1SD, 95% Confidence Interval [CI] 1.33 -2.21, p<0.001), diabetes 
mellitus (HR: 1.89 95%CI 1.20-2.96, p=0.005), heart failure (HR: 1.60, 95%CI 1.01-2.54, p=0.044), 
history of stroke/TIA (HR: 1.96, 95%CI 1.25-3.06, p=0.003) and urinary 11-dehydro-TxB2 (HR: 1.64 
per 1 SD, 95%CI 1.42-1.89, p<0.001). 
When we analyzed only CV deaths (table 3, panel B), we found that age (p<0.001), diabetes 
mellitus (p=0.004), history stroke/TIA (p=0.022), and urinary 11-dehydro-TxB2 (p<0.001) were 
positively associated with the outcome.  Conversely, statin use was inversely associated with CV 
death (p=0.037). 
 Risk prediction metrics 
Cardiovascular events. In order to assess calibration we compared observed vs. predicted CVEs at 
each time point (Figure 1, supplemental material). The goodness of fit is very good, and the line is 
not significantly different from the 45 degrees line (p=0.64). The C-index for the Cox model 
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without TxB2 is 0.70, while including TxB2 increased it to 0.76. IDI for TxB2 was computed as 0.06 
(p=0.007, 95%CI: 0.01 - 0.13). 
Cardiovascular deaths. In order to assess calibration we compared observed vs. predicted CV 
deaths at each time point (Figure 2, supplemental material). The goodness of fit is very good, and 
the line is not significantly different from the 45 degrees line (p=0.86). The C-index for the Cox 
model without TxB2 is 0.75, while including TxB2 increased it to 0.80. IDI for TxB2 was computed as 
0.08 (p=0.019, 95%CI: 0.01 - 0.17). 
Bleeding events  
During follow-up, 105 hemorrhages (27 major and 78 minor) occurred. Patients who experienced a 
bleeding event had lower values of urinary 11-dehydro-TxB2 (87 [49-136] vs. 100 [59-183]; 
p=0.025) and, as expected, a higher mean HAS-BLED score (2.0±0.96 vs. 1.69±0.94; p=0.02). A 
significant inverse correlation between HAS-BLED score and 11-dehydro-TxB2 levels was found (r: -
0.11, p=0.002). After dividing population according to tertiles of urinary 11-dehydro-TxB2 values, a 
non-significant trend in the proportion of patients who bled was observed: 21.4% patients in the 
first, 19.9% in the second and 12.6% in the third tertile (p=0.052 among groups). The difference 
was significant, when we compared the first to the third tertile (p=0.013). Kaplan-Meier analysis 
showed a significant inverse rate of bleeding events across tertiles of urinary 11-dehydro-TxB2 
(Log-Rank test, p=0.024). 
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Discussion 
This study provides novel data that urinary 11-dehydro-TxB2 is associated with cardiovascular 
events in anticoagulated AF patients. 
Previous studies have shown that urinary 11-dehydro-TxB2 levels are predictive of cardiovascular 
events in patients at risk of athero-thrombotic complications.12 In a secondary prevention trial,12 a 
nested case-control study comparing patients who experienced or not cardiovascular events found 
that urinary 11-dehydro-TxB2 levels were predictive of the risk of MI and cardiovascular death. 
This finding was confirmed in the CHARISMA trial,24 which found that urinary 11-dehydro-TxB2 
levels were associated with an increased risk of stroke, MI or cardiovascular death.24 
In our study, we measured baseline urinary 11-dehydro-TxB2 levels and analyzed the relationship 
between this variable and vascular outcomes during a follow-up of about 3 years. All patients 
included in the study were at high risk of stroke as evident by the high CHA2DS2-VASc score, and 
were on good quality anticoagulation control, as reflected by the average TTR.25 As expected, a 
residual vascular risk remained, and the annual rate of cerebrovascular events in our study was 
1.1% per year, which is similar to that reported in recent clinical studies.9, 26 Furthermore, 1.7% 
patients/year suffered from MI and cardiac revascularization, which is consistent with Roldàn et 
al.27, who found a rate MI of 1.83%/year, and apparently in contrast with recent clinical trials with 
non-vitamin K oral anticoagulants (NOACs). In particular, the annual rate of MI is about 1% 
(ranging from 0.53%/year in the RE-LY trial28, to 1.1%/year in the ROCKET AF study29) in AF 
patients treated with warfarin, and even lesser in those treated with NOACs (from 0.53%/year in 
the ARISTOTLE trial30 to 0.9%/year in the ROCKET AF study29). The reason for this difference 
cannot be fully established at the moment, but different populations’ age may account for this. 
Thus, the average age of our population is relatively higher than that reported in the trials with 
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NOACs, which is consistent with a previous study indicating that age >75 years is a risk factor for 
MI in AF31. 
While we confirm previous data on the association between urinary 11-dehydro-TxB2 levels and 
cardiovascular events, the novelty of the present study is our demonstration that urinary 11-
dehydro-TxB2 levels were associated with an increased risk of CVEs and cardiovascular death in an 
AF cohort already on OACs. Whilst urinary 11-dehydro-TxB2 levels do not fully reflect platelet-
thromboxane A2 formation,
32 this finding may suggest a potential role for platelets promoting 
vascular complications in some AF patients despite being on adequate OACs. Among the 
predictors of urinary 11-dehydro-TxB2 levels, previous history of cardiac events was associated 
with urinary 11-dehydro-TxB2 levels suggesting a potentially major interplay between coronary 
heart disease (CHD) and platelet activation in AF.  
Analysis of the relationship between 11-dehydro-TxB2 levels and bleeding showed that higher 
urinary 11-dehydro-TxB2 levels were associated with lower risk of bleeding; accordingly an inverse 
association between HAS-BLED and urinary 11-dehydro-TxB2 was detected. This is in contrast with 
a previous finding showing a direct relationship between urinary 11-dehydro-TxB2 and bleeding, 
but different populations and designs do not allow a direct comparison of these data.24 The 
biologic plausibility of our finding is in the probable inverse association between platelet activation 
and bleeding risk. 
The study has clinical implications and limitations. The present study would suggest that in AF on 
adequate oral anticoagulation, persistent platelet activation, as assessed by urinary 11-dehydro-
TxB2, is associated with vascular events. Patients with a clinical history of CHD were associated 
with enhanced urinary 11-dehydro-TxB2 suggesting that AF patients with previous CHD is a sub-
set which could be benefit from warfarin in combination with antiplatelet treatment. However, a 
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recent retrospective study on this specific sub-setting denied this possibility as no beneficial effect 
but a higher risk of bleeding has been observed in AF patients treated with warfarin plus aspirin33. 
Statins may represent an interesting option to be investigated as they possess antithrombotic 
effects by interfering with clotting system and, overall, by lowering platelet 11-dehydro-TxB2
34, 35. 
Notably, statins reduce the risk of cardiovascular events in primary and secondary prevention 
trials36, 37 and could be therefore useful in combination with warfarin to reduce the residual 
cardiovascular risk in patients with AF. Randomized study is, however, necessary to investigate the 
effectiveness of warfarin plus statins in patients with AF. Finally, inhibitor of TxB2 receptors
38, 39 
may represent another option in which this drug category could be investigated on top of oral 
anticoagulants. 
Whilst this was a prospective study, it was conducted in a single Italian center, including patients 
with average age >70 years and a coexistence of a serious vascular risk profile. Other limitations 
of this study include the relatively low number of patients and CVEs, the potential for residual 
confounding, the observational study design with the resulting inability to establish causal 
relations, the uncertain generalizability to other races/ethnicities. A last limitation is the lack of a 
control group of patients with similar characteristics but without AF. 
In conclusion, urinary 11-dehydro-TxB2 levels is associated with residual risk of cardiovascular 
events in anticoagulated AF patients. Such association is particularly evident in AF patients with a 
history of coronary heart disease, who, therefore, may be potential candidates for additional 
antithrombotic strategies as part of the holistic approach to managing this common arrhythmia40. 
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Figure legend 
Figure 1. Kaplan-Meier curves estimate of cardiovascular events according to tertiles of 11-
dehydro-thromboxane B2 levels. 
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Table 1. Baseline characteristics of the study cohort and according the occurrence of 
cardiovascular events. 
 Whole cohort 
n=837 
Cardiovascular events 
p value 
No (n=738) Yes (n=99) 
Age (years) 73.2±8.5 72.9±8.6 75.5±7.4 0.001 
Women (%) 43.6 44.0 40.4 0.52 
Body mass index (kg/m2) 27.2±4.7 27.2±4.7 27.3±4.2 0.88 
Smokers (%) 9.9 9.8 11.1 0.72 
CHA2DS2-VASc score
# 3 [2-4] 3 [2-4] 4 [3-5] <0.001 
Time in therapeutic range (%) 63.8±17.2 64.2±17.2 59.3±16.5 0.09 
Urinary 11-dehydro-TxB2
# 
100.0 [56.5-
181.0] 
98.0 [51.0-
170.0] 
185.0 [109.0-
400.0] 
<0.001 
HAS-BLED score# 2 [1-2] 1 [1-2] 2 [1-2] 0.60 
Arterial Hypertension 
(treated) (%) 
92.8 92.5 94.9 0.53 
Diabetes mellitus (%) 19.8 18.4 30.3 0.007 
Heart failure (%) 17.7 15.7 32.3 <0.001 
History of stroke/TIA (%) 16.7 15.0 29.3 0.001 
History of MI/ Cardiac 
Revascularization (%) 
24.0 22.4 36.4 0.004 
Anti-platelets (%) 7.0 7.3 5.1 0.53 
Statins (%) 37.4 37.4 37.4 0.99 
CVEs: cardiovascular events, MI: myocardial Infarction, TIA: transient ischemic attack, TxB2: 
thromboxane B2 
#data expressed as median and interquartile range. 
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Table 2. Baseline characteristics according to tertiles of urinary 11-dehydro-thromboxane B2 
 1st tertile 
(<70 ng/mg 
creatinine) 
2nd tertile 
(70-150 ng/mg 
creatinine) 
3rd tertile 
(>150 ng/mg 
creatinine) 
P value 
1st vs. 
3rd  
Age (years) 72.8±8.0 73.6±8.8 73.2±8.6 0.56 
Women (%) 39.1 45.7 45.8 0.19 
Body mass index (kg/m2) 27.1±4.5 27.2±4.6 27.4±4.9 0.74 
Smokers (%) 12.2 7.9 9.8 0.24 
CHA2DS2-VASc score
# 3 [2-4] 3 [2-4] 3 [2-5] 0.038 
Time in therapeutic range (%) 65.5±17.3 62.2±17.3 63.6±16.7 0.21 
HAS-BLED score# 2 [1-2] 2 [1-2] 1 [1-2] 0.001 
Arterial Hypertension (treated) (%) 91.5 91.8 95.1 0.18 
Diabetes mellitus (%) 19.9 20.0 19.6 0.99 
Heart failure (%) 15.5 18.2 19.2 0.49 
History of stroke/TIA (%) 15.5 14.6 19.9 0.20 
History of MI/ Cardiac 
Revascularization (%) 
21.4 23.6 26.9 0.31 
Anti-platelets (%) 9.6 6.1 5.6 0.14 
MI: myocardial Infarction, TIA: transient ischemic attack.  
#data expressed as median and interquartile range. 
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Table 3. Adjusted hazard ratios, based on a Cox proportional Hazards model according to 
selected variables. 
Panel A. CV Events p HR 95%CI 
Age per 1 SD <0.001 1.72 1.33 2.21 
Women 0.26 0.78 0.51 1.20 
Arterial Hypertension (treated) 0.63 0.83 0.32 2.14 
Diabetes Mellitus 0.005 1.89 1.20 2.96 
Smoking 0.26 1.48 0.75 2.90 
Heart Failure 0.044 1.60 1.01 2.54 
History of Stroke/TIA 0.003 1.96 1.25 3.06 
History of MI/Cardiac Revascularization 0.59 1.14 0.71 1.84 
Anti-platelets 0.89 1.07 0.41 2.77 
Statins 0.83 0.95 0.61 1.49 
Urinary 11-dehydro-TxB2 per 1SD <0.001 1.64 1.42 1.89 
Time in Therapeutic Range 0.96 0.99 0.98 1.02 
 
Panel B. CV deaths p HR 95%CI 
Age per 1 SD <0.001 2.04 1.43 2.92 
Women 0.43 0.79 0.45 1.41 
Arterial Hypertension (treated) 0.90 1.10 0.24 4.92 
Diabetes Mellitus 0.004 2.43 1.33 4.43 
Smoking 0.79 1.16 0.39 3.50 
Heart Failure 0.11 1.67 0.90 3.10 
History Stroke/TIA 0.022 2.00 1.10 3.63 
History of MI/Cardiac Revascularization 0.39 1.33 0.70 2.54 
Anti-platelets 0.56 1.44 0.42 4.99 
Statins 0.037 0.49 0.25 0.96 
Urinary 11-dehydro-TxB2 per 1SD <0.001 1.66 1.36 2.02 
Time in Therapeutic Range 0.49 0.98 0.96 1.02 
CI: confidence interval, CVE: cardiovascular event, HR: hazard ratios, MI: myocardial Infarction, 
TIA: transient ischemic attack, TxB2: Thromboxane B2. 
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